Skip to main content
. 2020 Jan 31;11:642. doi: 10.1038/s41467-019-14065-6

Fig. 3. AZD1480 alleviated sevoflurane-promoted lung metastasis through blocking IL-6/JAK/STAT3 pathway.

Fig. 3

a In the 4T1 mouse model, tumor bearing mice were orally administrated with vehicle or AZD1480 one day before surgery and the administration continued once a day until the end of the experiment. b Bioluminescent image of ex vivo lung and c quantitative photon intensity of lung were used to measure the metastatic burdens. Again, sevoflurane significantly promoted lung metastasis than propofol (p = 0.002, one-way ANOVA + Tukey post hoc test). Treatment with AZD1480 remarkably reduced sevoflurane-promoted lung metastasis (n = 6 for groups treated with vehicle and n = 5 for groups treated with AZD1480, p = 0.003, one-way ANOVA + Tukey post hoc test). The line within each box represents the median. Upper and lower edges of each box represent the first and third quantiles. The whiskers represent the lowest and highest value. d Quantification of metastatic nodule based on (e) lung histology confirmed the bioluminescent analysis with significant more macro-metastatic nodules in sevoflurane group compared to propofol group or AZD1480 group (n = 6 for groups treated with vehicle and n = 5 for groups treated with AZD1480; sevoflurane vs propofol, p = 0.008; sevoflurane vs sevoflurane + AZD1480, p = 0.03; two-way ANOVA + Dunnett’s post hoc tests;). Scale bar: 20× = 2 mm, 40× = 600 μm, 100× = 300 μm. f AZD1480 treatment significantly reduced the phosphorylated STAT3 (p-Tyr705) level in the lungs of sevoflurane group by Western blot analysis (n = 6 for groups treated with vehicle and n = 5 for groups treated with AZD1480, p = 0.015, two-way ANOVA + Dunnett’s post hoc tests). Data are shown as the mean ± S.D. Source data are provided as a Source Data file.